A
Aimei Health Technology Co., Ltd.
AFJKUCIK 0001979005NasdaqEmerging GrowthBlank ChecksFY ends Dec 31
Period
FY 2024
Revenue
—
Net Income
$2.55M
Total Assets
$73.81M
Equity
$-1.48M
Shares Out
6.12M
Op. Cash Flow
$-672.3K
Business
Aimei Health Technology Co., Ltd. is a blank check company formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It offers services to identify, negotiate and consummate initial business combinations and to provide target companies access to the U.S. public markets, including due diligence, structuring, and regulatory and listing support. Its activities are organized around sourcing and evaluating healthcare targets (biopharmaceuticals, medical technology/devices, diagnostics and related services). It pursues targets globally, with primary sourcing in North America, Europe and the Asia Pacific region and distribution of public securities through U.S. capital markets.
Summary from filing dated 2025-03-28
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | Dec 31, 2025 2025-12-31 | Dec 31, 2024 2024-12-31 |
|---|---|---|---|
| General, administrative and operational costs | 835,759 | 1 | |
| Loss from operations | −835,759 | −1 | |
| Other income: | — | — | |
| Interest Income | 2 | 4 | |
| Total other income, net | 2 | 4 | |
| NET INCOME | 1 | 3 | |
| Weighted Average Shares Outstanding | 6 | 9 | |
| Weighted Average Shares Outstanding, Diluted | 6 | 9 | |
| Earnings Per Share (Basic) | 0.34 | 0.56 | |
| Earnings Per Share (Diluted) | 0.34 | 0.56 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | Dec 31, 2025 2025-12-31 | Dec 31, 2024 2024-12-31 |
|---|---|---|---|
| ASSETS | — | — | |
| Current assets: | — | — | |
| Cash and Cash Equivalents | 2,929 | 28,208 | |
| Prepaid Expenses | — | 2,176 | |
| Total current assets | 2,929 | 30,384 | |
| Assets held in trust account | 12 | 74 | |
| TOTAL ASSETS | 12 | 74 | |
| LIABILITIES, TEMPORARY EQUITY AND SHAREHOLDERS’ DEFICIT | — | — | |
| Current liabilities: | — | — | |
| Other Current Liabilities | 447,997 | 299,514 | |
| Short-Term Debt | 2 | 227,700 | |
| Other Non-Operating Current Liabilities | 899,601 | 289,780 | |
| Total current liabilities | 3 | 816,994 | |
| Deferred Compensation, Non-Current | 690,000 | 690,000 | |
| TOTAL LIABILITIES | 4 | 2 | |
| Commitments and contingencies (Note 7) | — | — | |
| Temporary Equity | 12 | 74 | |
| Shareholders’ deficit: | — | — | |
| Total Stockholders' Equity | 213 | 213 | |
| Retained Earnings | −4 | −1 | |
| Total shareholders’ deficit | −4 | −1 | |
| TOTAL LIABILITIES, TEMPORARY EQUITY AND SHAREHOLDERS’ DEFICIT | 12 | 74 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | Dec 31, 2025 2025-12-31 | Dec 31, 2024 2024-12-31 |
|---|---|---|---|
| Cash flows from operating activities: | — | — | |
| Allocation of net income | 1 | 3 | |
| Adjustments to reconcile net income to net cash used in operating activities: | — | — | |
| Interest earned on cash held in trust | 2 | 4 | |
| Change in operating assets and liabilities: | — | — | |
| Prepaid expenses | −2,176 | 2,176 | |
| Due to a related company | −120,000 | −120,000 | |
| Accrued expenses | 148,483 | 274,673 | |
| Net cash used in operating activities | −565,100 | −672,289 | |
| Cash flows from investing activities: | — | — | |
| Cash withdrawn from Trust Account in connection with redemption | 65 | — | |
| Extension payments deposited in Trust Account | 2 | 277,700 | |
| Net cash provided by (used in) investing activities | 64 | −277,700 | |
| Cash flows from financing activities: | — | — | |
| Proceeds from Debt Issuance | 2 | 277,700 | |
| Advance from related party | 539,821 | 119,780 | |
| Redemption of ordinary shares | 65 | — | |
| Net cash provided by (used in) financing activities | −63 | 397,480 | |
| NET CHANGE IN CASH | −25,279 | −552,509 | |
| CASH, END OF YEAR | — | — | |
| CASH, END OF YEAR | — | — | |
| Non-cash investing and financing activities | — | — | |
| Remeasurement of ordinary shares subject to possible redemption | 2 | 4 | |
| Extension funds attributable to ordinary shares subject to redemption | 2 | 277,700 |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro